CNS Pharmaceuticals, Inc. (CNSP)

CNS Pharmaceuticals, Inc. stock has experienced significant fluctuations, decreasing by -82.56% over the last six months. Key events include a reverse stock split at a 1:50 ratio on February 21, 2025. The aggregate sales price of shares was increased to $30.2 million on July 30, 2024, and further to $43.5 million on March 20, 2025. As of March 20, 2025, the company had sold 2,522,755 shares for gross proceeds of approximately $23.75 million. In January 2026, a new CEO outlined a strategic evaluation, and in November 2025, the company reported its Q3 financial results, with a net loss of approximately $3.3 million, an improvement from $5.6 million in 2024. The company also reported its Q2 2025 financial results, maintaining a cash position of $12.1 million, expected to sustain operations into the second half of 2026.

No information indicating demand seasonality for CNS Pharmaceuticals, Inc.'s products or services was found. Demand is primarily driven by clinical trials, regulatory approvals, and the medical need for effective therapies.

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing anti-cancer drugs for brain and central nervous system tumors. Their primary drug candidates are Berubicin, an anthracycline in Phase I and II trials for glioblastoma multiforme, and TPI 287, an abeotaxane designed to stabilize microtubules and inhibit cell division. The company holds a worldwide exclusive license for Berubicin.

CNS Pharmaceuticals, Inc. is headquartered in Houston, Texas, United States. Further details on its operational geographic footprint are not extensively available.

No specific information regarding CNS Pharmaceuticals, Inc.'s brand reputation was found. Reputation is closely tied to the scientific credibility of its research, clinical trial outcomes, and interactions with regulatory bodies and the medical community.

CNS Pharmaceuticals, Inc. has a mixed ownership structure. Approximately 2.27% to 2.50% of the company's stock is held by institutional investors, insiders hold approximately 60.17%, and public companies and individual investors own about 37.33%. Major institutional owners include DRW Securities, LLC, and UBS Group AG. John Climaco owns the most shares among individuals.